Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: Scent diffuser for electronic device cases, purses and other personal complements. It's made of a light mesh, a thin absorbent piece and a waterproof plastic sheet. It diffuses essence fragrances.

Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: A process for producing surface postcrosslinked water-absorbing polymer particles, wherein the water-absorbing polymer particles are coated, before, during or after the surface postcrosslinking, with at least one basic salt of a trivalent metal cation and a monovalent carboxylic acid anion.

Abstract: The present invention relates to a process for producing polymer composites suitable for absorbing and storing aqueous liquids and to the polymer composites obtainable by this process. The invention further relates to the use of these polymer composites.

Abstract: The use of water-absorbing polymer particles for dewatering feces, the water-absorbing polymer particles being obtainable by polymerizing a foamed monomer solution or suspension, drying the polymeric foam and grinding the dried foam.

Abstract: This application discloses compounds according to generic Formula (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula (I) and at least one carrier, diluent or excipient.

Abstract: This application discloses compounds according to generic Formula I: (I) wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit BTK. The compounds disclosed herein are useful to modulate the activity of BTK and treat diseases associated with excessive BTK activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: This application discloses the Btk inhibitor compounds 6-tert-Butyl-8-fluoro-2-{3-hydroxymethyl-4-[1-methyl-5-(1?-methyl-1?,2?,3?,4?,5?,6?-hexahydro-[3,4?]bipyridinyl-6-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2H-phthalazin-1-one, 2-(2-{3-[5-(5-Azetidin-1-ylmethyl-1-methyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxy methyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-Butyl-2-[2-hydroxymethyl-3-(5-{5-[(2-methoxy-ethylamino)-methyl]-pyridin-2-ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2H-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.

Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: This application discloses compounds according to generic Formula I wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: A process for preparing water-absorbing polymeric foams by polymerization of a foamed aqueous monomer solution or suspension, comprising an ethylenically unsaturated monomer which bears acid groups and may be at least partly neutralized, a crosslinker, a photoinitiator and a surfactant.

Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.

Abstract: The present invention relates to a process for producing water-absorbent polymer particles by polymerizing droplets of a monomer solution in a surrounding heated gas phase and flowing the gas cocurrent through the polymerization chamber, wherein the temperature of the gas leaving the polymerization chamber is 130° C. or less, the gas velocity inside the polymerization chamber is at least 0.5 m/s, and the droplets are generated by using a droplet plate having a multitude of bores.

Abstract: The present invention relates to microcapsules comprising a capsule core and a capsule wall, obtainable by a process comprising the free-radical polymerization of an oil-in-water emulsion which comprises the following constituents: 30 to 90% by weight based on the total weight of the monomers of one or more monomers (monomers I) from the group comprising C1-C24-alkyl esters of acrylic acid and/or methacrylic acid, acrylic acid, methacrylic acid, maleic acid, fumaric acid and itaconic acid 10 to 70% by weight based on the total weight of the monomers of one or more ethylenically unsaturated crosslinkers (monomers II), where at least 10% by weight, based on the total weight of the monomers I, II and III, is a highly branched polymeric crosslinker, 0 to 30% by weight based on the total weight of the monomers of one or more monounsaturated monomers (monomer III), which are different from the monomers I, and a hydrophobic core material, to a process for their preparation and to their use.

Abstract: A feminine hygiene absorbent article comprising water-absorbing polymer particles, obtainable by polymerization of a foamed monomer solution or suspension, drying, grinding and classification.

Abstract: A process for preparing water-absorbing polymer particles, comprising polymerisation of a foamed aqueous monomer solution or suspension, drying, grinding and classification, whereas the process further comprising adjusting the amount of foaming agent in the aqueous monomer solution by admixing the aqueous monomer solution with a foaming agent of 1% to 15% by weight based on the amount of ethylenically unsaturated monomer and keeping the solution on a pressure of 6 bar to 15 bar and then expanding the solution.

Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.